Moderna, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Moderna, Inc. (MRNA) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$6.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-07-31
- Moderna, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$6.00M, a 146.15% decline year-over-year.
- Moderna, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$20.00M, a 200.00% decline year-over-year.
- Moderna, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $18.00M.
- Moderna, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $4.00M, a 95.12% decline year-over-year.
- Moderna, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $55.00M, a 51.33% decline from fiscal 2024.
- Moderna, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $113.00M, a 54.25% decline from fiscal 2023.
- Moderna, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $247.00M.
- Moderna, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$346.00M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month as first filed | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month as first filed | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month as first filed | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$6.00M 10-Q · filed 2026-07-31 | -$26.00M 10-Q · filed 2026-07-31 | -$8.00M derived: sum of 3 quarters · filed 2026-07-31 | -$4.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2026-03-31 | -$20.00M 10-Q · filed 2026-07-31 | -$2.00M derived: sum of 2 quarters · filed 2026-07-31 | $2.00M derived: sum of 3 quarters · filed 2026-07-31 | $15.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-12-31 | $18.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $22.00M derived: sum of 2 quarters · filed 2026-02-20 | $35.00M derived: sum of 3 quarters · filed 2026-07-31 | $55.00M 10-K · filed 2026-02-20 | ||||
| 2025-09-30 | $4.00M 10-Q · filed 2025-11-06 | $17.00M derived: sum of 2 quarters · filed 2026-07-31 | $37.00M 10-Q · filed 2025-11-06 | $16.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-06-30 | $13.00M 10-Q · filed 2026-07-31 | $33.00M 10-Q · filed 2026-07-31 | $12.00M derived: sum of 3 quarters · filed 2026-07-31 | $94.00M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-03-31 | $20.00M 10-Q · filed 2026-05-01 | -$1.00M derived: sum of 2 quarters · filed 2026-05-01 | $81.00M derived: sum of 3 quarters · filed 2026-05-01 | $111.00M derived: sum of 4 quarters · filed 2026-05-01 | ||||
| 2024-12-31 | -$21.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $61.00M derived: sum of 2 quarters · filed 2026-02-20 | $91.00M derived: sum of 3 quarters · filed 2026-02-20 | $113.00M 10-K · filed 2026-02-20 | ||||
| 2024-09-30 | $82.00M 10-Q · filed 2025-11-06 | $112.00M derived: sum of 2 quarters · filed 2025-11-06 | $134.00M 10-Q · filed 2025-11-06 | $222.00M derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-06-30 | $30.00M 10-Q · filed 2025-08-01 | $52.00M 10-Q · filed 2025-08-01 | $140.00M derived: sum of 3 quarters · filed 2026-02-20 | $192.00M derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-03-31 | $22.00M 10-Q · filed 2025-05-01 | $110.00M derived: sum of 2 quarters · filed 2026-02-20 | $162.00M derived: sum of 3 quarters · filed 2026-02-20 | $166.00M derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2023-12-31 | $88.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $140.00M derived: sum of 2 quarters · filed 2026-02-20 | $144.00M derived: sum of 3 quarters · filed 2026-02-20 | $247.00M 10-K · filed 2026-02-20 | ||||
| 2023-09-30 | $52.00M 10-Q · filed 2024-11-07 | $56.00M derived: sum of 2 quarters · filed 2024-11-07 | $159.00M 10-Q · filed 2024-11-07 | $140.00M derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-06-30 | $4.00M 10-Q · filed 2024-08-01 | $107.00M 10-Q · filed 2024-08-01 | $88.00M derived: sum of 3 quarters · filed 2025-02-21 | -$23.00M derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-03-31 | $103.00M 10-Q · filed 2024-05-02 | $84.00M derived: sum of 2 quarters · filed 2025-02-21 | -$27.00M derived: sum of 3 quarters · filed 2025-02-21 | -$83.00M derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2022-12-31 | -$19.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | -$130.00M derived: sum of 2 quarters · filed 2025-02-21 | -$186.00M derived: sum of 3 quarters · filed 2025-02-21 | -$346.00M 10-K · filed 2025-02-21 | ||||
| 2022-09-30 | -$111.00M 10-Q · filed 2023-11-03 | -$167.00M derived: sum of 2 quarters · filed 2023-11-03 | -$327.00M 10-Q · filed 2023-11-03 | -$382.00M derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-06-30 | -$56.00M 10-Q · filed 2023-08-03 | -$216.00M 10-Q · filed 2023-08-03 | -$271.00M derived: sum of 3 quarters · filed 2024-02-23 | -$256.00M derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2022-03-31 | -$160.00M 10-Q · filed 2023-05-04 | -$215.00M derived: sum of 2 quarters · filed 2024-02-23 | -$200.00M derived: sum of 3 quarters · filed 2024-02-23 | -$185.00M derived: sum of 4 quarters · filed 2024-02-23 | ||||
| 2021-12-31 | -$55.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | -$40.00M derived: sum of 2 quarters · filed 2024-02-23 | -$25.00M derived: sum of 3 quarters · filed 2024-02-23 | -$27.00M 10-K · filed 2024-02-23 | ||||
| 2021-09-30 | $15.00M 10-Q · filed 2022-11-03 | $30.00M derived: sum of 2 quarters · filed 2022-11-03 | $28.00M 10-Q · filed 2022-11-03 | $26.00M derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-06-30 | $15.00M 10-Q · filed 2022-08-03 | $13.00M 10-Q · filed 2022-08-03 | $11.00M derived: sum of 3 quarters · filed 2023-02-24 | $8.00M derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2021-03-31 | -$2.00M 10-Q · filed 2022-05-04 | -$4.00M derived: sum of 2 quarters · filed 2023-02-24 | -$7.00M derived: sum of 3 quarters · filed 2023-02-24 | $7.00M derived: sum of 4 quarters · filed 2023-02-24 | ||||
| 2020-12-31 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | -$5.00M derived: sum of 2 quarters · filed 2023-02-24 | $9.00M derived: sum of 3 quarters · filed 2023-02-24 | $1.00M 10-K · filed 2023-02-24 | $1.20M 10-K · filed 2021-02-26 | |||
| 2020-09-30 | -$3.00M 10-Q · filed 2021-11-04 | -$3.47M 10-Q · filed 2020-10-30 | $11.00M derived: sum of 2 quarters · filed 2021-11-04 | $3.00M 10-Q · filed 2021-11-04 | $2.98M 10-Q · filed 2020-10-30 | $1.85M derived: sum of 4 quarters · filed 2022-02-25 | ||
| 2020-06-30 | $14.00M 10-Q · filed 2021-08-05 | $14.38M 10-Q · filed 2020-08-06 | $6.00M 10-Q · filed 2021-08-05 | $6.45M 10-Q · filed 2020-08-06 | $4.85M derived: sum of 3 quarters · filed 2022-02-25 | $4.94M derived: sum of 4 quarters · filed 2022-02-25 | ||
| 2020-03-31 | -$8.00M 10-Q · filed 2021-05-06 | -$7.93M 10-Q · filed 2020-05-07 | -$9.15M derived: sum of 2 quarters · filed 2022-02-25 | -$9.06M derived: sum of 3 quarters · filed 2022-02-25 | -$6.91M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2019-12-31 | -$1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | -$1.06M derived: sum of 2 quarters · filed 2022-02-25 | $1.09M derived: sum of 3 quarters · filed 2022-02-25 | $3.00M 10-K · filed 2022-02-25 | $3.12M 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $89.00K 10-Q · filed 2020-10-30 | $2.24M derived: sum of 2 quarters · filed 2020-10-30 | $4.15M 10-Q · filed 2020-10-30 | $3.75M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2019-06-30 | $2.15M 10-Q · filed 2020-08-06 | $4.06M 10-Q · filed 2020-08-06 | $3.66M derived: sum of 3 quarters · filed 2021-02-26 | $4.75M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2019-03-31 | $1.91M 10-Q · filed 2020-05-07 | $1.51M derived: sum of 2 quarters · filed 2021-02-26 | $2.60M derived: sum of 3 quarters · filed 2021-02-26 | $3.74M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2018-12-31 | -$398.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $689.00K derived: sum of 2 quarters · filed 2021-02-26 | $1.83M derived: sum of 3 quarters · filed 2021-02-26 | -$163.00K 10-K · filed 2021-02-26 | ||||
| 2018-09-30 | $1.09M 10-Q · filed 2019-11-06 | $2.23M derived: sum of 2 quarters · filed 2019-11-06 | $235.00K 10-Q · filed 2019-11-06 | |||||
| 2018-06-30 | $1.14M 10-Q · filed 2019-08-08 | -$852.00K 10-Q · filed 2019-08-08 | ||||||
| 2018-03-31 | -$1.99M 10-Q · filed 2019-05-09 | |||||||
| 2017-12-31 | -$754.00K 10-K · filed 2020-02-27 | |||||||
| 2016-12-31 | $163.00K 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |